ALN-VSP: Interim Phase I data

Interim data from 12 evaluable patients in an open-label, dose-escalation Phase I trial showed that 0.1-0.4 mg/kg IV ALN-VSP every 2 weeks was well tolerated with no signs of hepatotoxicity. At the 0....